AM1710

AM1710, a CB2 agonist, belongs to the class of cannabinoids known as cannabilactones. Cannabilactones are characterized by the presence of a carbonyl group instead of the 6,6-dimethyl group typically found in the classical tricyclic structure of cannabinoids.

AM1710 may be used to study the effects of CB2 agonists on neuropathic nociception induced by the antiretroviral agent Zalcitabine, in a mouse model.

AM1710 is a highly potent and selective CB2 agonist that displays 54-fold selectivity for CB2 over CB1. AM1710 is a low potency inverse agonist/antagonist at CB1 in vitro but is not a functional CB1 antagonist in vivo. It inhibits chemotherapy-induced neuropathic pain in rodents while delaying the development of morphine tolerance and reduced naloxone-precipitated opioid withdrawal.